Literature DB >> 26897666

Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study.

Klaus Murbraech1, Torgeir Wethal2, Knut B Smeland3, Harald Holte4, Jon Håvard Loge5, Espen Holte2, Assami Rösner6, Håvard Dalen7, Cecilie E Kiserud3, Svend Aakhus8.   

Abstract

OBJECTIVES: This study assessed the prevalence and associated risk factors for valvular dysfunction (VD) observed in adult lymphoma survivors (LS) after autologous hematopoietic stem cell transplantation (auto-HCT), and to determine whether anthracycline-containing chemotherapy (ACCT) alone in these patients is associated with VD.
BACKGROUND: The prevalence of and risk factors for VD in LS after auto-HCT is unknown. Anthracyclines may induce heart failure, but any association with VD is not well-defined.
METHODS: This national cross-sectional study included all adult LS receiving auto-HCT from 1987 to 2008 in Norway. VD was defined by echocardiography as either more than mild regurgitation or any stenosis. Observations in LS were compared with a healthy age- and gender-matched (1:1) control group.
RESULTS: In total, 274 LS (69% of all eligible) participated. Mean age was 56 ± 12 years, mean follow-up time after lymphoma diagnosis was 13 ± 6 years, and 62% of participants were males. Mean cumulative anthracycline dosage was 316 ± 111 mg/m(2), and 35% had received radiation therapy involving the heart (cardiac-RT). VD was observed in 22.3% of the LS. Severe VD was rare (n = 9; 3.3% of all LS) and mainly aortic stenosis (n = 7). We observed VD in 16.7% of LS treated with ACCT alone (n = 177), corresponding with a 3-fold increased VD risk (odds ratio: 2.9; 95% confidence interval: 1.5 to 5.8; p = 0.002) compared with controls. Furthermore, the presence of aortic valve degeneration was increased in the LS after ACCT alone compared with controls (13.0% vs. 2.9%; p < 0.001). Female sex, age >50 years at lymphoma diagnosis, ≥3 lines of chemotherapy before auto-HCT, and cardiac-RT >30 Gy were identified as independent risk factors for VD in the LS.
CONCLUSIONS: In LS, ACCT alone was significantly associated with VD and related to valvular degeneration. Overall, predominantly moderate VD was prevalent in LS, and longer observation time is needed to clarify the clinical significance of this finding.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anthracyclines; autologous hematopoietic stem cell transplantation; echocardiography; lymphoma survivors; radiation therapy; valvular dysfunction

Mesh:

Substances:

Year:  2016        PMID: 26897666     DOI: 10.1016/j.jcmg.2015.06.028

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  11 in total

1.  Speckle-Tracking Echocardiography in Cardio-Oncology and Beyond.

Authors:  Raymundo A Quintana; Linh P Bui; Rohit Moudgil; Nicolas Palaskas; Saamir Hassan; Jun-Ichi Abe; Elie Mouhayar; Syed Wamique Yusuf; Antonieta Hernandez; Jose Banchs
Journal:  Tex Heart Inst J       Date:  2020-04-01

2.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Authors:  Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

Review 3.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 4.  Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.

Authors:  Wendy J Bottinor; Christopher K Migliore; Carrie A Lenneman; Marcus F Stoddard
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

Review 5.  Advanced Imaging Modalities to Monitor for Cardiotoxicity.

Authors:  Andreas Seraphim; Mark Westwood; Anish N Bhuva; Tom Crake; James C Moon; Leon J Menezes; Guy Lloyd; Arjun K Ghosh; Sarah Slater; Heather Oakervee; Charlotte H Manisty
Journal:  Curr Treat Options Oncol       Date:  2019-08-08

6.  Rate of Progression of Aortic Stenosis in Patients With Cancer.

Authors:  Katia Bravo-Jaimes; Nicolas L Palaskas; Jose Banchs; Nadia I Abelhad; Alveena Altaf; Sushanth Gouni; Juhee Song; Saamir A Hassan; Cezar Iliescu; Anita Deswal; Syed Wamique Yusuf
Journal:  Front Cardiovasc Med       Date:  2021-03-18

7.  Mortality after transcatheter aortic valve replacement for aortic stenosis among patients with malignancy: a systematic review and meta-analysis.

Authors:  Muhammad Umer Siddiqui; Omar Yacob; Joey Junarta; Ahmed K Pasha; Farouk Mookadam; Mamas A Mamas; David L Fischman
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.298

8.  Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer: A case report.

Authors:  Xiaoyan Liu; Yanlin Zhu; Xue Lin; Ligang Fang; Xiaowei Yan
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Severe mitral regurgitation, an unusual manifestation of chemotherapy-induced cardiotoxicity.

Authors:  Ahmad Mirdamadi; Afsoon Emami Naeini; Mohaddeseh Behjati
Journal:  J Res Med Sci       Date:  2017-12-26       Impact factor: 1.852

10.  Treatment for lymphoma and late cardiovascular disease risk: A systematic review and meta-analysis.

Authors:  Chelsea R Stone; Alexis T Mickle; Devon J Boyne; Aliya Mohamed; Doreen M Rabi; Darren R Brenner; Christine M Friedenreich
Journal:  Health Sci Rep       Date:  2019-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.